TEST:

MammaPrint®

S2206 trial using neoadj durvalumab with standard chemo in Breast cancer ER+HER2 stage II-III mammaprint ultra high patients. The next big step, using genomic firms in decision taking during the neoadj setting. (@DrMedOnco)

Breast cancer has standardized signatures (PAM50, Mammaprint) so that is plausible. I would love a standard insulin measure. Whether it's output or clearance, exposure to high ins is a risk factor some diseases. Seems metabolites could be standardized too w the right gear for all (@LWellberg)

I think it is unlikely that there were any secretory TNBC cases in the Mammaprint training data. The NTRK angle is interesting. You need a trial of adjuvant larotrectinib for breast like the ADAURA trial for EGFR mutant resected lung ca. (@UnfrznCavemanMD)

Ok another difficult case to crowdsource! 3.5cm pT2N0 secretory carcinoma of the breast, TNBC. Mammaprint basal/high risk. S/p lumpectomy. + LVI. Would you give? #onctwitter #bcsm (@Dr_RShatsky)

#bcsm clinical question. CT2N1 ER 50% PR0% her2 0, invasive ductal. Mammaprint high, Blueprint BASAL. Gets neoadjuvant ddACT. Path has ypT1b residual. Do u give adjuvant abemaciclib? ()

MammaPrint and BluePrint tests provide accurate results for thousands of women. Regardless of age.* #SGBCC2023 #breastcancer *MammaPrint® FFPE is CE-marked, and FDA-cleared for 18 years or older. ()

NCCN Adds MammaPrint Gene Expression Assay to Breast Cancer Guidelines https://t.co/QYDm41PyyM via @onclive #BCSM Women in ultralow risk category can avoid collateral damage from treatment. Big step forward. Congrats @DrLauraEsserman, @LVVPrint ()

Glad to see the expansion of tools for profiling of breast cancer. MammaPrint offers ultra low-risk threshold which can make the difference in doing less safely. Coming soon: response predictive subtypes (testing in ISPY) to further tailor Tx in the high-risk setting @LVVPrint ()

@Agendia is delighted to attend the post SABCS Belgium tonight and tomorrow #mammaprint #blueprint #breastcancer ()

#sabcs2022 MammaPrint & extended endocrine therapy benefit in IDEAL trial *MP low (not ultralow nor high):derive benefit from extended ET @gary_lyman @OncoAlert ()

#SABCS22 MammaPrint in the IDEAL trial: may predict benefit from extended endocrine therapy (10 vs 7.5 yrs) in the genomic-low-risk but not in the high-risk or ultra-low-risk. Unclear if clinical risk plays a role. How do we reconcile this data with prior data from BCI? ()

MammaPrint & extended endocrine therapy benefit in IDEAL trial *MP high: no significant benefit *MP low: derive benefit from extended ET *MP ultralow: risk cannot be evaluated in IDEAL Consistent with prior NSABP-B42 analysis. Laura van't Veer @UCSFCancer #SABCS22 ()

Tomorrow in San Antonio #mammaprint #blueprint #SABCS2022 ()

Join Agendia at #EBCC13 in Barcelona! Please stop by booth #B3 to discuss the latest data on #MammaPrint and #BluePrint, our comprehensive genomic #breastcancer tests. ()

Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer https://t.co/srq627E7HR Both the original and the update of the Raster trial are so juicy! ()

Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥ 70 years with ultralow risk of distant recurrence: A population-based cohort study. https://t.co/tqovS3Hgai @NienkedeGlas @WilliamDale_MD @rochgerionc @myCARG #GeriOnc ()

Drs. @VeredStearns & Raquel Nunes discuss the role of Oncotype DX and MammaPrint, two validated gene signatures that are commonly used for premenopausal women with HR-positive, HER2-negative #BreastCancer. https://t.co/8j5kUVKqun #ASCODailyNews #bcsm ()

Otto Metzger giving a comprehensive clinical analysis of #Lobular at #ILCSymposium 10% ILC are High Genomic Risk by Mammaprint @Otto_DFCI @LobularIreland @elbcc @sflomos @CANCERPREV1 @IrishCancerSoc @CancerInstIRE @damirvareslija @CancerCentreIre @NiTriona ()

I-SPY2: pCR by molecular subtype for HR+/HER2- breast cancer. Higher pCR rates in Mammaprint High2, Blueprint Basal, and RPS immune+ signature. Future randomization planned based on RPS subtype. @laura_huppert @hoperugo of @UCSFCancer #ASCO22 #bcsm ()

#CedarsSinaiCancer at #ASCO22. Dr. Alice Chung will be presenting “Identification of transcriptional changes with #MammaPrint and BluePrint in early-stage breast cancer after neoadjuvant #chemotherapy.” @ASCO @CedarsSinaiMed @CSCancerCare @AGiulianoMD #Breastcancer ()

So ISPY2 enrolls all mammaprint high risk who have tumors >2.5cm so not just TNBC. We have had de-escalation longer than Keynote 522 data was standard of care so most have not gotten adjuvant IO. ISPY2 trial ends at surgery so up to providers what they want to do adjuvantly #bcsm ()

#bcsm Time for another controversial treatment poll! Young patient (under35), Luminal B tumor (by Oncotype or Mammaprint), pT2N0 (4cm). ()

#BreastCancer #Monterrey #Oncology #ClinicalCase #ClinicalScenario #MammaPrint #Cancer #Genomic #Adjuvant #Chemotherapy @drdonsdizon @rodbox44 @BrizioMoreno @Dr_Zamudio @AChargy @DrHectorDiaz @DrDAGP_OM @Dra_CVillarreal @anelcabrera @mivan_eduardo @hectordelamora @AlethiaAlvarez ()

#CedarsSinaiCancer at #SABCS21. Dr. Alice Chung and Dr. Armando Giuliano @AGiulianoMD are co-authors on “#Mammaprint and Blueprint are prognostic of outcome following neoadjuvant #Chemotherapy” presented at Poster Session 4. #CedarsSinai @SABCSSanAntonio (@CSCancerCare)